Table 3 HRs for progression-free survival by subgroup
Groups | PFS | P | cHR | 95% CI | aHR | 95% CI | |||
|---|---|---|---|---|---|---|---|---|---|
Age | > 45 | 12 | 1.000 | 1.000 | |||||
≤ 45 | 16 | 0.006 | 0.611 | 0.429 | 0.870 | 0.569 | 0.398 | 0.814 | |
Gender | Male | 12 | 1.000 | ||||||
Female | 14 | 0.577 | 1.064 | 0.855 | 1.324 | ||||
Smoking | No | 13 | 1.000 | ||||||
Yes | 12 | 0.962 | 1.006 | 0.780 | 1.297 | ||||
Family history | No | 12 | 1.000 | ||||||
Yes | 13 | 0.313 | 0.864 | 0.651 | 1.148 | ||||
Disease history | No | 13 | 1.000 | ||||||
Yes | 10 | 0.158 | 1.578 | 0.838 | 2.972 | ||||
Histopathologic type | AD | 12 | 1.000 | ||||||
Non AD | 11 | 0.988 | 1.004 | 0.583 | 1.730 | ||||
Differentiation | High | 13 | 1.000 | ||||||
Middle | 12 | 0.730 | 0.948 | 0.701 | 1.282 | ||||
Low | 12 | 0.470 | 0.864 | 0.582 | 1.283 | ||||
Stage | I | 15 | 1.000 | 1.000 | |||||
II | 12 | 0.209 | 1.507 | 0.795 | 2.857 | 1.039 | 0.729 | 1.481 | |
III | 12 | 0.037 | 1.706 | 1.032 | 2.821 | 1.232 | 0.943 | 1.610 | |
IV | 13 | 0.095 | 1.750 | 0.908 | 3.372 | 1.585 | 0.975 | 2.579 | |
Operation | Radical | 18 | 1.000 | ||||||
Palliative | 12 | 0.023 | 1.369 | 1.044 | 1.794 | 1.816 | 1.217 | 2.711 | |
Adjuvant chemotherapy | No | 13 | 1.000 | ||||||
Yes | 12 | 0.624 | 0.936 | 0.720 | 1.218 | ||||
Adjuvant radiation | No | 13 | 1.000 | ||||||
Yes | 12 | 0.723 | 1.042 | 0.830 | 1.309 | ||||
TKI | Gefitinib | 13 | 1.000 | ||||||
Erlotinib Hydrochloride | 12 | 0.303 | 1.171 | 0.867 | 1.581 | ||||
Icotinib | 13 | 0.177 | 1.225 | 0.912 | 1.646 | ||||
Others | 11 | 0.200 | 1.489 | 0.810 | 2.735 | ||||
EGFR mutation | 19 del | 12 | 1.000 | ||||||
21 L858R | 14 | 0.302 | 0.946 | 0.851 | 1.052 | ||||